FB
Forte Biosciences, Inc.
FBRX · NASDAQ
$76.99 +0.03% (+$0.02)
Market Cap $1.58B
P/E Ratio -
Div. Yield -
ROE 94.82%
Bulios Fair Price
$63.69
17.3% downside
Current Price
$76.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, FBRX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 8.58x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 16.25%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 49.43%
ROE 94.82%
ROA 42.74%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 10.01x
Int. coverage N/A
Stability
19 /100
Unstable Beta 2.65x
EPS volatility 47.09%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about FBRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul A. Wagner
Employees
23
Headquarters
Dallas
Upcoming events
13 NOV
Earnings
Upcoming earnings report